Key result
Inadequately validated assays force reconsideration of plasma proCPU as a prothrombotic risk factor.
Answers are grounded in this paper and cite their sources.
Accurate and validated assays are essential to properly evaluate the role of proCPU (TAFI) as a potential prothrombotic risk factor.
BACKGROUND: The importance of carboxypeptidase U (CPU) as a novel regulator of the fibrinolytic rate has attracted much interest during recent years. CPU circulates in plasma as a zymogen, proCPU, that can be activated by thrombin, thrombin-thrombomodulin (T-Tm), or plasmin. Given that the proCPU concentration in plasma is far below its K(m) for activation by the T-Tm complex, the formation of CPU will be directly proportional to the proCPU concentration. A low or high proCPU plasma concentration might therefore tip the balance between profibrinolytic and antifibrinolytic pathways and thereby cause a predisposition to bleeding or thrombosis. CONTENT: To measure plasma proCPU concentrations, different methods have been developed based on 2 different principles: antigen determination and measurement of CPU activity after quantitative conversion of the proenzyme to its active form by addition of T-Tm. The major drawbacks that should be kept in mind when analyzing clinical samples by both principles are reviewed. CONCLUSIONS: proCPU is a potential prothrombotic risk factor. Evaluation of its relationship with thrombosis requires accurate assays. Many assays used in different clinical settings are inadequately validated, forcing reconsideration of conclusions made in these reports.
No takes yet. Share an insight, caveat, or question.
Willemse et al. (2005) conducted a review in Thrombosis. proCPU assays was evaluated. Many assays used to measure plasma proCPU concentrations are inadequately validated, forcing reconsideration of conclusions made in clinical reports regarding its role as a prothrombotic risk factor.
Synapse has enriched 10 related papers. Consider them for comparative context: